A Study of ABT-165 in Subjects With Solid Tumors

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-09-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: therapycancercoronaryantitumor
  Phrases that lowered it: efficacyscreening visitthe screeningadvanced solidpharmacokinetics
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Maximum age: 99 (lowers risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 23 (lowers risk) · Sponsor's track record
• Number of arms: 5 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 96.1% (raises risk) · Drug's FDA history
• Design: sequential (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 17 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.2% (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors NCT02565758 · started 2015 · scored riskier than 16% of active trials completed
• A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors NCT02955251 · started 2016 · scored riskier than 15% of active trials completed
• A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors NCT03071757 · started 2017 · scored riskier than 34% of active trials completed
• Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients NCT05109650 · started 2022 · scored riskier than 34% of active trials terminated
• A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors NCT03595059 · started 2018 · scored riskier than 17% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.